omniture
信达生物制药(苏州)有限公司 Innovent BiologicsInc

Latest News

Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021

SAN FRANCISCO and SUZHOU, China, Sept. 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-09-17 08:00 5271

Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-09-08 08:00 7052

Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)

SAN FRANCISCO and SUZHOU, China, Sept. 2, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-09-02 08:00 4775

Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021

SAN FRANCISCO and SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-08-30 08:00 3140

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

SAN FRANCISCO and SUZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-08-27 08:00 4406

Innovent Announced 2021 Interim Results with Total Revenue of RMB 1,941.8 Million and Accelerated Global R&D Footprint

SAN FRANCISCO and SUZHOU, China, Aug. 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-08-25 20:53 4377

Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet

SAN FRANCISCO and SUZHOU, China, Aug. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-08-18 08:00 3512

Innovent Announces IBI306 (anti-PCSK-9 antibody) Meets the Primary Endpoint in a Phase 3 Clinical Study for Chinese Heterozygous Familial Hypercholesterolemia

SAN FRANCISCO and SUZHOU, China, Aug. 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-08-12 08:00 8861

Innovent Announces the Establishment of the Scientific Advisory Board

SAN FRANCISCO and SUZHOU, China, Aug. 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-08-09 08:04 4139

Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology

SAN FRANCISCO and SUZHOU, China, Aug. 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-08-06 08:00 22517

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-26 08:00 5857

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 16, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-16 08:00 7297

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-12 08:12 3541

Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China

SAN FRANCISCO and SUZHOU, China, July 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-07-06 08:00 3502

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal

SAN FRANCISCO and SUZHOU, China, June 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-06-29 08:00 4480
1 ... 567891011 ... 14